002907 华森制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.8942.0266.8427.49910.580
总资产报酬率 ROA (%)2.5331.7595.4095.2557.097
投入资产回报率 ROIC (%)2.8852.0176.2696.1548.400

边际利润分析
销售毛利率 (%)57.89354.97859.33552.73548.066
营业利润率 (%)13.7946.62613.86012.21015.574
息税前利润/营业总收入 (%)11.9044.91614.16112.44116.307
净利润/营业总收入 (%)11.2994.72812.53210.84713.506

收益指标分析
经营活动净收益/利润总额(%)97.90884.08191.69790.15974.389
价值变动净收益/利润总额(%)-4.801-10.910-2.407-1.2833.976
营业外收支净额/利润总额(%)-0.767-7.071-0.5440.104-0.284

偿债能力分析
流动比率 (X)5.0544.7424.5284.3203.475
速动比率 (X)4.3393.9383.9853.7043.012
资产负债率 (%)12.32412.61313.72928.53931.346
带息债务/全部投入资本 (%)-2.248-2.368-2.32913.681--
股东权益/带息债务 (%)-4,437.155-4,206.132-4,275.219608.029512.365
股东权益/负债合计 (%)711.414692.802628.379250.398219.021
利息保障倍数 (X)-6.670-3.86537.74157.04020.990

营运能力分析
应收账款周转天数 (天)77.811100.52587.21170.3500.000
存货周转天数 (天)146.944154.033136.536110.7230.000